Immuno-Oncology | Specialty

Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma

November 4th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the role for immunotherapy and targeted agents in patients with BRAF-positive melanoma.

Speed Critical With Anaplastic Thyroid Cancer Diagnosis, Treatment

November 3rd 2016

Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.

Targeting CD47 May Open "Exciting" Door to Novel Combos

November 3rd 2016

Gregory L. Beatty, MD, PhD, who focuses his research on understanding the role of innate immunity in gastrointestinal malignancies, discusses CD47 as an anticancer target.

Dr. Mohammed Haseebuddin on Expanding Role for Immunotherapy in RCC

November 3rd 2016

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discuses why continued research into immunotherapy in clear cell renal cell carcinoma (RCC) is important, particularly in the adjuvant and neoadjuvant settings.

Dr. David L. Rimm on the Continued Role for PD-L1 Testing in NSCLC

November 3rd 2016

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the continued role for PD-L1 testing to predict response with checkpoint inhibitors in non­–small cell lung cancer (NSCLC).

Jena D. French on Anti-PD-1/Lenvatinib Combo in Differentiated Thyroid Cancer

November 3rd 2016

Jena D. French, PhD, instructor of medicine, division of endocrinology, metabolism and diabetes, Anschutz Medical Campus, University of Colorado, discusses the potential for immunotherapy combinations with lenvatinib in differentiated thyroid cancer.

Dr. Pal on Sequencing Challenges for the Treatment of Patients With RCC

November 3rd 2016

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the challenges with sequencing the therapies available for patients with renal cell carcinoma (RCC). Pal shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Dr. Schoenfeld on Preventing Immune Suppression With Radiation and Immunotherapy Combos

November 2nd 2016

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses challenges with immune suppression with radiation and immunotherapy combinations.

Expert Discusses Promise of Nivolumab in Advanced Bladder Cancer

November 1st 2016

Results from the phase II CheckMate-275 trial demonstrated favorable safety and efficacy with the PD-1 inhibitor nivolumab as a second-line treatment for patients with metastatic urothelial cancer who have progressed on first-line chemotherapy.

Using All Modalities Key to Expanding Immunotherapy Success in Oncology

November 1st 2016

While immunotherapy is currently only beneficial in select cancers, it is possible for this type of treatment to eventually work for all patients.

The Future of Non-Driver Lung Adenocarcinoma

October 31st 2016

Cost Considerations in Non-Driver NSCLC Management

October 31st 2016

Nintedanib in Lung Adenocarcinoma: Managing Toxicities

October 31st 2016

Practical Considerations With Nintedanib in Lung Adenocarcinoma

October 31st 2016

Practical Implications of the LUME-Lung 1 Findings

October 31st 2016

Lung Adenocarcinoma: Patient Selection With Ramucirumab vs Nintedanib

October 31st 2016

Differentiating Among Anti-VEGF Therapies in Lung Adenocarcinoma

October 31st 2016

Non-Driver NSCLC: Clinical Decisions in Rapidly Progressing Disease

October 31st 2016

PD-L1 Status in Second-Line Lung Adenocarcinoma

October 31st 2016

Options in Second-Line Non-Squamous NSCLC

October 31st 2016